The World Health Organization has announced a new package of guidance and access measures aimed at improving care for children and adolescents with sickle cell disease, with particular emphasis on places where diagnosis and treatment remain difficult to obtain.
WHO estimates that sickle cell disease contributed to about 81,100 deaths among children younger than five in 2021. It says nearly 80% of cases occur in sub-Saharan Africa.
The new effort combines clinical guidance with work intended to improve access to quality-assured, affordable and child-appropriate medicines.
What sickle cell disease is
Sickle cell disease is an inherited disorder of haemoglobin, the protein in red blood cells that carries oxygen.
A change in the beta-globin gene can cause haemoglobin molecules to form long polymers when oxygen levels fall. This can distort normally flexible red blood cells into a rigid sickle shape.
These abnormal cells can break down prematurely and obstruct small blood vessels. The result can include severe anaemia, episodes of intense pain, infection, stroke and progressive damage to organs.
Because the genetic change is present from birth, early diagnosis and preventive care can substantially alter a child's risk of complications.
What WHO is trying to change
WHO says its updated package focuses on both how sickle cell disease should be managed and whether children can actually obtain the medicines and services recommended.
That distinction matters. A treatment guideline has limited impact if diagnostic testing, suitable formulations, laboratory monitoring or reliable medicine supply are unavailable.
WHO's announcement specifically highlights the need for quality-assured and child-friendly medicines, particularly in countries carrying the largest burden of disease.
Why access remains a major problem
Sickle cell disease can be managed more effectively when health systems identify affected children early and provide preventive and disease-modifying care.
But implementation requires several pieces to work together: newborn or early-childhood diagnosis, vaccination and infection prevention, access to appropriate medicines, monitoring for complications, trained health workers and referral pathways for serious disease.
When one part of this chain is missing, children can present only after severe complications have developed.
Why this is important beyond a new guideline
Sickle cell disease is a useful example of the difference between discovering an effective treatment and delivering it at population scale.
Many of the clinical tools needed to reduce complications are already known. The continuing burden therefore reflects not only biological difficulty, but also gaps in diagnosis, medicine formulation, supply and health-system delivery.
WHO's new package is important because it treats those implementation problems as part of the medical problem rather than as an afterthought.
What to watch next
The meaningful indicators will be measurable changes in newborn screening, medicine availability, treatment uptake, hospitalizations, severe complications and childhood mortality in high-burden countries.
Those outcomes, rather than publication of the guidance itself, will show whether the initiative changes care in practice.
Primary source
- World Health Organization, WHO moves to expand access to lifesaving sickle cell treatment and care for children, 1 September 2026: https://www.who.int/news/item/01-09-2026-who-moves-to-expand-access-to-lifesaving-sickle-cell-treatment-and-care-for-children